Home › Funds › Vestal Point Capital, LP › BCAX

Vestal Point Capital, LP position in BCAX

BICARA THERAPEUTICS INC · Health Care

Vestal Point Capital, LP reported holding 5,250,000 shares of BCAX (BICARA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$155.9M, representing 3.64% of its reported portfolio and ranking #7 among its reported holdings. Vestal Point Capital, LP has disclosed BCAX holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

Latest position (Q2 2026)5.25M sh
Reported value held$155.87M
Portfolio Weight3.64%
First reportedQ3 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vestal Point Capital, LP's BCAX position evolved

Vestal Point Capital, LP first disclosed a stake in BCAX in Q3 2024 at 425,000 shares (US$10.8M). The position peaked in Q2 2026 at 5,250,000 shares, worth US$155.9M. Across 8 filings, Vestal Point Capital, LP increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 5,250,000 shares valued at US$155.9M — a reduction of -175,000 shares quarter over quarter.. Notable position changes include a 67% increase in Q4 2024 (shares fell 25% over the following quarter), a 290% increase in Q1 2025 (shares fell 29% over the following quarter), a 81% increase in Q2 2025 (shares rose 70% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 425.00K $10.82M New
Q4 2024 710.00K $12.37M Add
Q1 2025 2.77M $36.08M Add
Q2 2025 5.00M $46.45M Add
Q3 2025 5.10M $80.53M Add
Q4 2025 3.58M $60.17M Reduce
Q1 2026 5.42M $107.90M Add
Q2 2026 5.25M $155.87M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCAX and 13F data

BCAX (BICARA THERAPEUTICS INC) is a Health Care company. 58 other funds we track also report a position in BCAX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$215.4M), Siren, L.L.C. (US$166.4M), Deep Track Capital, LP (US$121.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCAX

All BCAX fund holders →

FAQ

How long has Vestal Point Capital, LP held BCAX?

Vestal Point Capital, LP has disclosed BCAX holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

What is Vestal Point Capital, LP's current position in BCAX?

As of Q2 2026, Vestal Point Capital, LP holds 5.25M shares of BCAX (BICARA THERAPEUTICS INC), valued at $155.87M, representing 3.64% of its reported portfolio and ranking #7.

Has Vestal Point Capital, LP been buying or selling BCAX?

In the latest 13F filing (Q2 2026), Vestal Point Capital, LP reduced its position in BCAX. The position peaked in Q2 2026 at 5.25M shares.

Which other funds hold BCAX?

Other major institutional holders of BCAX include RA CAPITAL MANAGEMENT, L.P., Siren, L.L.C., Deep Track Capital, LP, among 58 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.